Lurbinectedin

Brand names: Zepzelca · Active ingredient: Lurbinectedin

In short: ZEPZELCA, in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs, is indicated for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab

Forms & strengthsFor injection: 4 mg of lurbinectedin as a sterile, preservative-free, white to off-white lyophilized powder in a single-dose vial for reconstitution prior to intravenous infusion.
LabelJazz Pharmaceuticals, Inc.
Label updatedOct 02, 2026

What is Lurbinectedin used for?

ZEPZELCA, in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs, is indicated for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin and etoposide.

Lurbinectedin dosage

The recommended dosage of ZEPZELCA in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs is 3.2 mg/m2 by intravenous infusion over 60 minutes every 21 days until disease progression or unacceptable toxicity.

Initiate treatment with ZEPZELCA only if absolute neutrophil count (ANC) is at least 1,500 cells/mm3 and platelet count is at least 100,000/mm3

.

When administering ZEPZELCA on the same day as atezolizumab or atezolizumab and hyaluronidase-tqjs, administer the chosen atezolizumab drug first. For the recommended dosage of atezolizumab or atezolizumab and hyaluronidase-tqjs refer to the respective Prescribing Information.

If discontinuation of atezolizumab or atezolizumab and hyaluronidase-tqjs is required due to an immune-related severe adverse event, treatment with ZEPZELCA may be continued at the same dose. If immune toxicity does not resolve or recurs despite discontinuation of atezolizumab, permanently discontinue ZEPZELCA.

The recommended dose reductions for adverse reactions are listed in Table 1.

Permanently discontinue ZEPZELCA in patients who require a dose interruption of greater than two weeks and in patients who are unable to tolerate the second dose reduction.

Dose Reduction | Total Dose

First

Second | 2.6 mg/m2 every 21 days

2 mg/m2 every 21 days

Dosage modifications for ZEPZELCA for adverse reactions are presented in Table 2.

a National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0.

b Patients who have not received primary prophylaxis of G-CSF with isolated Grade 4 neutropenia (neutrophil count less than 500 cells/mm3) may receive G-CSF prophylaxis rather than undergo lurbinectedin dose reduction.

Adverse Reaction | Severitya | Dosage Modification

Neutropeniab

| Grade 4

or

Any grade febrile neutropenia | •Withhold ZEPZELCA until absolute neutrophil count (ANC) is ≥ 1,500 cells/mm3

•Resume ZEPZELCA at a reduced dose

Thrombocytopenia

| Grade 3 with bleeding

or

Grade 4 | •Withhold ZEPZELCA until platelet ≥ 100,000/mm3

•Resume ZEPZELCA at reduced dose

Hepatotoxicity

| Grade 2 | •Withhold ZEPZELCA until Grade ≤ 1

•Resume ZEPZELCA at same dose

Grade ≥ 3 | •Withhold ZEPZELCA until Grade ≤ 1

•Resume ZEPZELCA at reduced dose or permanently discontinue

Rhabdomyolysis

| Grade 2 | •Withhold ZEPZELCA until Grade ≤ 1

•Resume ZEPZELCA at same dose

Grade ≥ 3 | •Permanently discontinue ZEPZELCA

Other Adverse Reactions

| Grade 2 | •Withhold ZEPZELCA until Grade ≤ 1

•Resume ZEPZELCA at same dose

Grade ≥ 3 | •Withhold ZEPZELCA until Grade ≤ 1

•Resume ZEPZELCA at reduced dose or permanently discontinue

Avoid coadministration of ZEPZELCA with strong or moderate CYP3A inhibitors. …

How to take Lurbinectedin — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Myelosuppression

Advise patients that ZEPZELCA can cause myelosuppression. Inform patients about the signs and symptoms of myelosuppression and to immediately contact their healthcare provider if signs or symptoms occur .

Hepatotoxicity

Advise patients that ZEPZELCA can cause hepatotoxicity and to contact their healthcare provider immediately if signs or symptoms occur .

Extravasation Resulting in Tissue Necrosis

Advise patients that administration of ZEPZELCA through a central venous catheter is recommended because extravasation of ZEPZELCA can cause skin and soft tissue injury, including necrosis requiring debridement. Advise patients to contact their healthcare provider immediately for signs or symptoms of extravasation. The time to onset of necrosis after extravasation may vary .

Rhabdomyolysis

Advise patients that rhabdomyolysis has been reported with the use of ZEPZELCA and to contact their healthcare provider immediately for signs and symptoms of rhabdomyolysis .

Embryo-Fetal Toxicity

•Advise pregnant women and females of reproductive potential of the potential risk to a fetus. …

Warnings & precautions

Do not take this medicine if: None.

ZEPZELCA can cause severe and fatal myelosuppression including febrile neutropenia and sepsis, thrombocytopenia and anemia.

Administer ZEPZELCA only to patients with baseline neutrophil count of at least 1,500 cells/mm3 and platelet count of at least 100,000/mm3. To reduce the risk of febrile neutropenia administer granulocyte colony-stimulating factor (G-CSF) [refer to Prescribing Information].

Monitor blood counts including neutrophils, red blood cells and platelets prior to each ZEPZELCA administration. For neutrophil count less than 500 cells/mm3 or any value less than lower limit of normal, administer G-CSF. Withhold, reduce the dose, or permanently discontinue ZEPZELCA based on severity .

In the IMforte study , primary prophylaxis of G-CSF was administered to 84% of patients. Based on laboratory values, decreased neutrophils occurred in 36%, including 18% Grade 3 or Grade 4 in patients who received ZEPZELCA in combination with atezolizumab. The median time to onset of Grade 3 and 4 decreased neutrophil cells was 31 days and a median duration of 10 days. Febrile neutropenia occurred in 1.7%. Sepsis occurred in 1%. There were 7 fatal infections: pneumonia (n=3), sepsis (n=3), and febrile neutropenia (n=1).

Based on laboratory values, decreased platelets occurred in 54%, including 15% Grade 3 or Grade 4 in patients who received ZEPZELCA in combination with atezolizumab. The median time to onset of Grade 3 and 4 decreased platelet cells was 31 days and a median duration of 12 days.

Based on laboratory values, decreased hemoglobin occurred in 51%, including 13% Grade 3 or Grade 4 in patients who received ZEPZELCA in combination with atezolizumab. The median time to onset of Grade 3 and 4 decreased hemoglobin was 64 days and a median duration of 8 days.

ZEPZELCA can cause hepatotoxicity which may be severe. …

Lurbinectedin side effects

The following clinically significant adverse reactions are described elsewhere in the labeling:

•Myelosuppression

•Hepatotoxicity

•Extravasation Resulting in Tissue Necrosis

•Rhabdomyolysis

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety population described in the WARNINGS AND PRECAUTIONS reflects exposure to ZEPZELCA in combination with intravenous atezolizumab in the IMforte study , in 242 patients with extensive stage small cell lung cancer (ES-SCLC) whose disease had not progressed after initial therapy with atezolizumab, carboplatin, and etoposide. Patients received ZEPZELCA 3.2 mg/m2 intravenously (IV) in combination with atezolizumab 1,200 mg IV every 21 days until disease progression or unacceptable toxicity. Among 242 patients who received ZEPZELCA in combination with intravenous atezolizumab, 34% were exposed for 6 months or longer and 8% were exposed for greater than one year. …

Drug interactions

Strong and Moderate CYP3A Inhibitors

Coadministration of ZEPZELCA with a strong or a moderate CYP3A inhibitor increases lurbinectedin systemic exposure , which may increase the incidence and severity of adverse reactions to ZEPZELCA.

Avoid grapefruit and Seville oranges during ZEPZELCA treatment, as these contain strong or moderate inhibitors of CYP3A.

Avoid coadministration of ZEPZELCA with strong or moderate CYP3A inhibitors. If coadministration cannot be avoided, reduce the dose of ZEPZELCA .

Strong CYP3A Inducers

Avoid coadministration of ZEPZELCA with strong CYP3A inducers. Coadministration of ZEPZELCA with a strong CYP3A inducer may decrease lurbinectedin systemic exposure, which may decrease the efficacy of ZEPZELCA .

About this medicine

ZEPZELCA is an alkylating drug. The chemical name of ZEPZELCA (lurbinectedin) is (1’R,6R,6aR,7R,13S,14S,16R)-8,14-dihydroxy-6’,9-dimethoxy-4,10,23-trimethyl-19-oxo-2’,3’,4’,6,7,9’,12,13,14,16-decahydro-6aH-spiro[7,13-azano-6,16-(epithiopropanooxymethano) [1,3]dioxolo[7,8]isoquinolino[3,2-b][3]benzazocine-20,1’-pyrido[3,4-b]indol]-5-yl acetate.

The molecular formula is C41H44N4O10S. The molecular weight is 784.87g/mol, and the chemical structure is:

ZEPZELCA for injection 4 mg is supplied as a lyophilized powder in a single-dose vial for reconstitution for intravenous use. The ZEPZELCA lyophilized formulation is comprised of 4 mg lurbinectedin, sucrose (800 mg), lactic acid (22.1 mg), and sodium hydroxide (5.1 mg). Before use, the lyophilizate is reconstituted by addition of 8 mL Sterile Water for Injection USP, yielding a solution containing 0.5 mg/mL lurbinectedin (the calculated concentration is 0.47 mg/mL based on the final volume of 8.5 mL). …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 632bb50c-3bcb-4c85-9056-fc33410550ae. Read the full official label on DailyMed.

Related medicines

Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate